NYSE:ABBV 17 August 2025 - 12 February 2026

AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday
····

AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday

New York, Feb 22, 2026, 15:09 EST — Market closed AbbVie heads into the new week after U.S. regulators approved a new first-line combination for chronic lymphocytic leukemia, pairing AstraZeneca’s Calquence with AbbVie’s Venclexta. The FDA said the regimen improved progression-free survival — the time before the disease worsens — versus standard chemoimmunotherapy in the AMPLIFY study.
February 22, 2026
Senolytic Drugs
··········

The Secret “Zombie Cell” Killers: Niche Senolytic Drugs Fighting Aging’s Clock

For centuries, people have searched for a fountain of youth. Today, scientists are zeroing in on an intriguing strategy – senolytic drugs – that might help turn back the biological clock. These compounds target the so-called “zombie cells” in our bodies, officially known as senescent cells, which stop dividing but refuse to die nature.com. As we age, these senescent cells accumulate and spew out harmful signals that drive inflammation, tissue damage, and aging itself nature.com. Senolytics are designed to selectively destroy these damaged cells, potentially slowing aging and alleviating many age-related conditions with a single treatment. Researchers discovered the first senolytic breakthrough in 2015, when a Mayo Clinic and Scripps Research team found that a combination of two compounds –
August 17, 2025